PhaseV has secured $50 million in Series A funding to advance its AI-driven platform for clinical development. The round was co-led by Accel and Insight Partners, with continued backing from Viola Ventures, EXOR, and LionBird, bringing the company’s total funding to $65 million.

The Boston-based company provides a vertical AI platform used by more than 30 pharmaceutical and biotech firms globally. Its technology supports clinical trial design, execution, and real-time operations across over 20 therapeutic areas including neurology, oncology, immunology, rare diseases, and metabolic conditions.

According to the company, the platform integrates patient-level data, real-world evidence, and peer-reviewed research to improve trial efficiency and outcomes. Reported results include a 50% reduction in trial costs, a 40% drop in both enrollment size and duration, and a 30% increase in likelihood of success. In one instance, PhaseV claims it helped a major pharmaceutical company shorten time to market by more than a year.

PhaseV’s offering includes applications for trial design (including Bayesian and adaptive models), causal machine learning to identify treatment-responsive subgroups, disease modelling, and site analytics for improved clinical operations.

“We’ve worked with PhaseV to detect clinically meaningful subgroups using causal ML,” said Stu Bailey, SVP at EMD Serono. “Their input has directly impacted our development plans, and we see continued potential to collaborate.”

The company believes traditional trial approaches are struggling to keep pace with the demands of modern drug development. It plans to use the investment to expand the platform’s capabilities and help more pharma and CRO partners transition to AI-enabled methods.

Accel partner Matt Robinson said PhaseV’s collaborations with top pharma firms reflect the industry’s appetite for tech-driven trial solutions.

Insight Partners’ Dylan Morris added that the company’s AI model ‘paves the way for a new era of clinical development’.